UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 1025, 2026

ASTRANA HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37392	95-4472349
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading ~~symbol~~Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ASTH	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~The~~On ~~stockholders~~June of25, ~~Astrana Health~~2026, ~~Inc.~~ ~~(the~~Glenn ~~“Company”)~~Sobotka, ~~approved~~ the ~~Astrana~~Chief ~~Health, Inc.~~Accounting ~~Amended~~Officer and ~~Restated 2024 Equity Incentive Plan~~principal ~~(as~~accounting ~~amended~~officer ~~and~~of ~~restated~~Astrana Health, Inc. (the “~~2024 Plan~~Company”), atand the ~~2026 Annual Meeting of Stockholders of the~~ Company ~~(the~~agreed ~~“Annual~~that ~~Meeting”) held on June 10, 2026~~Mr. ~~The~~Sobotka ~~2024~~will ~~Plan~~retire ~~was~~from ~~previously~~his ~~approved~~positions with by the Company’s ~~Board~~effective as of ~~Directors~~August ~~(the~~7, ~~“Board”)~~2026. As ~~amended~~Mr. ~~and~~Sobotka’s ~~restated,~~retirement ~~the~~is ~~number~~not ofthe ~~shares~~result of ~~the~~any ~~Company’s~~disagreement ~~common~~with ~~stock reserved for issuance under~~ the ~~2024 Plan has been increased~~Company byon ~~1,000,000~~any ~~shares,~~matter ~~and~~relating ~~the~~to ~~term of~~ the ~~2024~~Company’s ~~Plan~~operations, ~~has been extended until March 24~~policies, ~~2036~~or practices.

AJohn ~~summary~~Vong, ofwho ~~the~~has ~~2024 Plan~~been isappointed ~~included~~as inSenior ~~Proposal~~Vice President – 4Accounting ofeffective July 1, 2026, will succeed Mr. Sobotka as the Company’s ~~Definitive~~principal ~~Proxy~~accounting ~~Statement~~officer, oneffective ~~Schedule~~as ~~14A~~of ~~filed~~August 7, ~~with~~2026. ~~the~~Mr. ~~Securities~~Vong, ~~and~~52, ~~Exchange~~has ~~Commission~~previously onserved ~~April 17, 2026~~as (the ~~“Proxy~~Company’s ~~Statement”),~~Group ~~which~~Vice ~~summary~~President, isAccounting ~~incorporated~~since inMarch ~~its~~2025. ~~entirety~~Prior ~~herein~~to ~~by reference~~that, Mr. ~~The~~Vong ~~summaries~~served ofas the ~~2024 Plan~~Company’s ~~contained~~Chief ~~herein~~Accounting Officer and inprincipal ~~the~~accounting ~~Proxy~~officer ~~Statement~~from doNovember ~~not~~2022 ~~purport~~ to beMarch ~~complete~~2025 and as ~~are~~its ~~subject~~Vice ~~to,~~President of Finance and ~~qualified~~Accounting infrom ~~their~~July ~~entirety~~2022 ~~by reference~~to November 2022. Prior to, joining the ~~full~~Company, ~~text~~Mr. Vong served as Vice President of ~~the~~Finance ~~2024~~and ~~Plan~~Accounting at Prospect Medical Systems, aInc. ~~copy~~from ofFebruary ~~which~~2016 isto ~~filed~~July 2022. Mr. Vong began his career as ~~Exhibit 10~~a certified public accountant with RSM.1 toMr. ~~this~~Vong ~~Current~~received ~~Report~~a onBachelor ~~Form 8-K~~of ~~and~~Science degree in Business Administration from the University of isCalifornia, ~~incorporated~~Riverside ~~herein~~and bya ~~reference~~Master of Business Administration degree from the University of California, Irvine.

~~Item~~Effective 5as of July 1, 2026, Mr.07 ~~Submission~~Vong’s ofannual ~~Matters~~base salary will increase to $320,000. Mr. Vong’s target bonus opportunity as a ~~Vote~~percentage of ~~Security~~his ~~Holders~~annual base salary for 2026 pursuant to his employee agreement remains unchanged.

~~The~~There ~~Company~~is ~~held~~no ~~its Annual~~arrangement ~~Meeting~~or onunderstanding ~~June~~between ~~10, 2026~~Mr. AtVong ~~the~~or ~~close~~any ofother person ~~business~~pursuant onto ~~April 14,~~which ~~2026,~~he ~~the~~was ~~record~~selected ~~date~~as ~~for~~principal ~~the~~accounting ~~Annual~~officer ~~Meeting~~of (the ~~“Record Date”)~~Company, and there ~~were~~are ~~55,713,532~~no ~~shares~~family ofrelationships ~~common stock, par value $0~~between Mr.~~001~~ ~~per~~Vong ~~share,~~and any of the Company’s ~~issued~~directors ~~and~~or ~~outstanding~~executive officers. AtThere ~~the Annual~~are ~~Meeting,~~no ~~there~~transactions ~~were~~to ~~present~~which inthe ~~person~~Company oris bya ~~proxy~~party ~~43,772,595~~and in ~~shares~~which ofMr. ~~the~~Vong ~~Company’s~~has ~~common~~a ~~stock,~~direct ~~representing~~or ~~stockholders entitled~~indirect tomaterial ~~cast~~interest ~~approximately~~that ~~78.6%~~would ofbe ~~the~~required ~~total~~to ~~outstanding~~be ~~eligible~~disclosed ~~votes~~under ~~and~~Item ~~constituting~~ 404(a) ~~quorum.~~of AtRegulation ~~the Annual Meeting:~~S-K.

1. Nine directors were elected to the Board, each to hold office until the 2027 Annual Meeting of Stockholders.

2. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.

3. The compensation program for the Company’s named executive officers as disclosed in Proxy Statement was approved, on an advisory, non-binding basis.

4. The 2024 Plan was approved.

The voting results for each such matter were as follows:

Proposal 1. Election of Directors

Nominee	For	Withheld	Broker Non-Votes
Kenneth Sim, M.D.	33,456,519	1,959,958	8,356,118
Thomas S. Lam, M.D., M.P.H.	33,486,509	1,929,968	8,356,118
John Chiang	34,104,046	1,312,431	8,356,118
Weili Dai	33,926,696	1,489,781	8,356,118
Linda Dong	33,330,641	2,085,836	8,356,118
J. Lorraine Estradas, R.N., B.S.N. M.P.H.	32,171,774	3,244,703	8,356,118
Mitchell W. Kitayama	33,320,506	2,095,971	8,356,118
Matthew Mazdyasni	33,610,789	1,805,688	8,356,118
David G. Schmidt	33,198,453	2,218,024	8,356,118

Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm

For		Against		Abstain		Broker Non-Votes
43,722,509		19,566		30,520		—

Proposal 3. Advisory Vote on Executive Compensation

For		Against		Abstain		Broker Non-Votes
34,119,199		1,209,072		88,206		8,356,118

Proposal 4. Approval of the 2024 Plan

For		Against		Abstain		Broker Non-Votes
34,679,879		701,303		35,295		8,356,118

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
10.1*		Astrana Health, Inc. Amended and Restated 2024 Equity Incentive Plan.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

* Management contract or compensatory plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASTRANA HEALTH, INC.
Date: June 10, 2026	By:	/s/ Brandon K. Sim
Date: July 1, 2026	By:	/s/ Brandon K. Sim
	Name:	Brandon K. Sim
	Title:	Chief Executive Officer and President

Filing Compare · Astrana Health, Inc.